| Item Type |
Article |
| ID |
|
| Preview |
| Image |
|
| Caption |
|
|
| Full text |
KAKEN_24659657seika.pdf
| Type |
:application/pdf |
Download
|
| Size |
:176.2 KB
|
| Last updated |
:Apr 11, 2016 |
| Downloads |
: 581 |
Total downloads since Apr 11, 2016 : 581
|
|
| Release Date |
|
| Title |
| Title |
脳腫瘍幹細胞抗原および微小環境を標的とした複合的免疫療法の開発
|
| Kana |
ノウシュヨウ カンサイボウ コウゲン オヨビ ビショウ カンキョウ オ ヒョウテキ ト シタ フクゴウテキ メンエキ リョウホウ ノ カイハツ
|
| Romanization |
Noshuyo kansaibo kogen oyobi bisho kankyo o hyoteki to shita fukugoteki meneki ryoho no kaihatsu
|
|
| Other Title |
| Title |
Immunotherapy targeting brain tumor stem cell antigen and niche
|
| Kana |
|
| Romanization |
|
|
| Creator |
| Name |
戸田, 正博
 |
| Kana |
トダ, マサヒロ
|
| Romanization |
Toda, Masahiro
|
| Affiliation |
慶應義塾大学・医学部・准教授
|
| Affiliation (Translated) |
|
| Role |
Research team head
|
| Link |
科研費研究者番号 : 20217508
|
| Name |
植田, 良
|
| Kana |
ウエダ, リョウ
|
| Romanization |
Ueda, Ryo
|
| Affiliation |
慶應義塾大学・医学部・共同研究員
|
| Affiliation (Translated) |
|
| Role |
Research team member
|
| Link |
科研費研究者番号 : 30317143
|
|
| Edition |
|
| Place |
|
| Publisher |
|
| Date |
| Issued (from:yyyy) |
2015
|
| Issued (to:yyyy) |
|
| Created (yyyy-mm-dd) |
|
| Updated (yyyy-mm-dd) |
|
| Captured (yyyy-mm-dd) |
|
|
| Physical description |
|
| Source Title |
| Name |
科学研究費補助金研究成果報告書
|
| Name (Translated) |
|
| Volume |
|
| Issue |
|
| Year |
2014
|
| Month |
|
| Start page |
|
| End page |
|
|
| ISSN |
|
| ISBN |
|
| DOI |
|
| URI |
|
| JaLCDOI |
|
| NII Article ID |
|
| Ichushi ID |
|
| Other ID |
|
| Doctoral dissertation |
| Dissertation Number |
|
| Date of granted |
|
| Degree name |
|
| Degree grantor |
|
|
| Abstract |
本研究では, グリオーマ細胞, 脳腫瘍幹細胞, およびグリオーマ組織において, 免疫抑制性のVEGF/VEGFR系が高発現していることを明らかにした。また, 再発悪性神経膠腫8症例に対してVEGFR1/2ペプチドワクチン療法を施行し, 重篤な有害事象なく2例の不変(stable disease : SD)が得られた。投与前後のVEGFR特異的T細胞(CTL)の解析(6症例)を行った結果, ワクチン後にVEGFR1特異的CTLが6例中6例, VEGFR2特異的CTLが6例中2例で誘導された。以上からVEGF阻害(腫瘍免疫抑制の制御および腫瘍血管新生抑制)による新たな免疫療法の有効性が示唆された。
In this study, we demonstrated that glioma cells and brain tumor stem cells (BTSCs) expressed highly VEGF (vascular endothelial growth factor) and VEGFR (vascular endothelial growth factor receptor) in vitro. Furthermore, VEGFR was shown to express highly within malignant glioma tissues compared with surrounding brain tissue. In a clinical study, we performed a novel immunotherapy using VEGFR1/VEGFR2 peptides in 8 patients with recurrent malignant glioma and analyzed the cytotoxic T lymphocytes (CTLs) specific to VEGFR1/VEGFR2. After the vaccination with VEGFR1/VEGFR2, CTLs specific to VEGFR1 were induced in 6 out of 6 patients analyzed and CTLs specific to VEGFR2 in 2 out of 6 patients. These results suggest that an immunotherapy using VEGFR1/2 peptides to inhibit the VEGF/VEGFR signal may be effective for the treatment of malignant glioma.
|
|
| Table of contents |
|
| Keyword |
|
| NDC |
|
| Note |
研究種目 : 挑戦的萌芽研究
研究期間 : 2012～2014
課題番号 : 24659657
研究分野 : 脳神経外科
|
|
| Language |
|
| Type of resource |
|
| Genre |
|
| Text version |
|
| Related DOI |
|
| Access conditions |
|
| Last modified date |
|
| Creation date |
|
| Registerd by |
|
| History |
|
| Index |
|
| Related to |
|
